Clinical Trials 2010 - Invest up to 50% less and be among the experts from the industry

North West Business Group29 - 30 September 2010, Frankfurt, Germany.
In the current environment where minimising cost and delivering ROI are critical themes within the pharma industry, improving your clinical trial infrastructure can ensure that time is not wasted and you are maximising your investments. Attend Clinical trials 2010, this two day meeting which is concise and packed with value, Presentations that will be case-study oriented, supplemented by panel discussions and network with leading practitioners to provide information to keep clinical trials goal-oriented, on-time and cost-effective. Take-aways will include presentations with information that can readily be adapted to clinical trial projects in your organization.The 2010 event is set to be a highlight in the clinical trial events calendar. What's more, it is widely accepted that there is nothing better than to learn from the experience of experts rather than trying to build that knowledge yourself.

The programme covers a wide range of topics including:

  • Clinical Trials in the 21st Century
  • Clinical trials in emerging economies: myth and reality
  • How to optimize the global patient recruitment process
  • Working with Academic Study Groups
  • How to attract and retain clinical trials in western countries
  • Outsourcing Innovative approaches
  • The effect of EU regulations on conducting clinical trials
  • Joins some of the experts like:
  • Astrazeneca, Clinical Research Director Europe
  • Grunenthal, Head of Clinical Operations
  • MDC, Senior PartnerProduct Specialist Clinical Business Intelligence Systems
  • Novartis, Chief Scientific Officer
  • Glaxo Smith Kline, Director Clinical Research
  • Actelion, Director, Global Clinical Development Affairs
  • Novartis, Head Clinical Operations
  • Lundbeck, Senior Specialist, Outsourcing
  • Janssen-Cilag, Head Clinical Trials
  • Sanofi-Aventis, Head of Clinical Research Unit
  • Bayer Health care, EDC Director
  • Pfizer, Associate Director Worldwide Regulatory Affairs & Quality Assurance
  • And many more...

Who should attend?
This conference is designed to attract key decision makers from the Pharmaceutical industry: Presidents, Managing Directors, Country Managers, General Managers, Vice Presidents, Regional Directors/ Heads, Directors, Department Heads, Managers.

For further information and registration, please visit:
http://nwbg.eu/all-events/clinical-trials-2010/

Most Popular Now

Bayer, Brigham and Women’s Hospital, and Massachus…

Bayer and Partners HealthCare's founding members Brigham and Women's Hospital (BWH) and Massachusetts General Hospital (MGH) today announced the launch of a joint lab to ...

AstraZeneca divests rights for Losec to Cheplaphar…

AstraZeneca has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arznei...

Cause of antibiotic resistance identified

Scientists have confirmed for the first time that bacteria can change form to avoid being detected by antibiotics in the human body. Studying samples from elderly patient...

Amgen announces positive results from two Phase 3 …

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (2012021...

Brilinta monotherapy in high-bleeding risk patient…

New data from TWILIGHT, a Phase IV independent trial (funded by AstraZeneca), showed that in patients at high-bleeding risk who underwent PCI and completed 3 months of du...

Novartis and Microsoft announce collaboration to t…

Novartis announced an important step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science pa...

Ian Read to retire as Executive Chairman of Pfizer…

Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman of the Board Ian C. Read has chosen to...

FDA approves first oral GLP-1 treatment for type 2…

The U.S. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along w...

Discovery of new source of cancer antigens may exp…

For more than a decade, scientist Stephen Albert Johnston and his team at Arizona State University's Biodesign Institute have pooled their energies into an often scoffed-...

Chinese activists protest the use of traditional t…

In the West, the number of people challenging scientific authority has been growing in past decades. This has, among other things, led to a decline in the support for mas...

Cheaper drug just as effective protecting heart in…

A new clinical trial conducted at The Ohio State University Wexner Medical Center found a cost-effective generic medication works just as well as a more expensive drug in...

Dengue virus becoming resistant to vaccines and th…

Researchers from Duke-NUS Medical School (DukeNUS), in collaboration with the Agency for Science, Technology and Research (A*STAR)'s Bioinformatics Institute (BII), and t...